Gel Mark Ultra Biopsy Site Marker - Marker, lesion localization, implantable

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Pieejams no:

Bard Australia Pty Ltd

Klase:

Class III

Ražojis:

SenoRx Inc 1625 W 3rd Street, Tempe, AZ, 82581 United States Of America

Ārstniecības joma:

40808 - Marker, lesion localization, implantable

Ārstēšanas norādes:

A disposable applicator containing resorbable polylactic acid/polyglycolic acid (PLA/PGA) pellets with an embedded titanium radiopaque wireform, intended for long term radiographic marking of the biospy site. Pellets are visible via ultrasound for approx. 6 weeks and resorbed in approx. 12 weeks. The pellets are deployed from the applicator through the biopsy device into the biopsy cavity. An implant used to radiographically mark breast tissue during a percutaneous breast biopsy procedure.

Autorizācija statuss:

A

Autorizācija datums:

2009-03-11